SeaCrest Wealth Management LLC Boosts Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

SeaCrest Wealth Management LLC raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,981 shares of the medical equipment provider’s stock after purchasing an additional 60 shares during the period. SeaCrest Wealth Management LLC’s holdings in Intuitive Surgical were worth $881,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ISRG. Norges Bank acquired a new stake in shares of Intuitive Surgical during the fourth quarter valued at about $1,313,238,000. Capital Research Global Investors acquired a new stake in shares of Intuitive Surgical during the first quarter valued at about $374,390,000. Assenagon Asset Management S.A. boosted its stake in shares of Intuitive Surgical by 111.7% in the first quarter. Assenagon Asset Management S.A. now owns 1,285,565 shares of the medical equipment provider’s stock valued at $513,056,000 after purchasing an additional 678,375 shares during the period. Coatue Management LLC boosted its stake in shares of Intuitive Surgical by 65.7% in the fourth quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock valued at $439,106,000 after purchasing an additional 516,054 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after purchasing an additional 493,126 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Craig H. Barratt sold 2,496 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $402.89, for a total transaction of $1,005,613.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Craig H. Barratt sold 2,496 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $402.89, for a total transaction of $1,005,613.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 584 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $404.41, for a total transaction of $236,175.44. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,226,681.46. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,309 shares of company stock valued at $6,642,470. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Trading Up 0.4 %

Shares of Intuitive Surgical stock traded up $1.78 during trading on Tuesday, reaching $483.94. The company’s stock had a trading volume of 468,634 shares, compared to its average volume of 1,543,256. The firm has a market cap of $171.65 billion, a PE ratio of 87.64, a P/E/G ratio of 4.97 and a beta of 1.39. The company has a 50-day moving average price of $444.48 and a two-hundred day moving average price of $408.57. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $488.48.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.18 EPS. On average, analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Morgan Stanley raised their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. The Goldman Sachs Group assumed coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective for the company. Citigroup raised their price objective on shares of Intuitive Surgical from $462.00 to $512.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $380.00 to $510.00 in a research note on Friday, August 2nd. Finally, Barclays lifted their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $442.30.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.